Ferumoxytol增强MRI可检测儿童及年轻成人骨肉瘤的关节与胸膜浸润
本研究回顾性纳入15例骨肉瘤儿童及年轻成人患者的18次MRI扫描,评估ferumoxytol纳米颗粒增强MRI能否区分肿瘤浸润与否的关节和胸膜腔。结果显示,注射ferumoxytol后24小时MRI上,所有肿瘤浸润的关节和胸膜腔积液均呈T1高信号,而无浸润者无强化,SNR和CNR差异有统计学意义(P=0.004)。而平扫、钆增强及注射后1小时ferumoxytol MRI均未见强化。
要点
- 注射ferumoxytol后24小时MRI上,肿瘤浸润的关节/胸膜腔积液呈T1高信号,无浸润者无强化。
- SNR和CNR在浸润组显著高于无浸润组(P=0.004),有助于鉴别。
- 平扫、钆增强及1小时ferumoxytol MRI均无法显示该强化差异。
关键影像表现/征象
- 注射ferumoxytol后24小时MRI显示,所有肿瘤浸润的关节和胸膜腔积液均呈阳性T1强化,无浸润者无强化。
- 肿瘤浸润的关节和胸膜腔积液的SNR(P=0.004)和CNR(P=0.004)显著高于无浸润者。
- 平扫MRI、钆增强MRI及注射ferumoxytol后1小时MRI均未显示关节或胸膜腔积液的强化,无论有无肿瘤浸润。
诊断标准与关键数值
- 以组织学或影像表现确定肿瘤浸润;24小时ferumoxytol增强MRI上关节或胸膜腔积液出现T1强化提示肿瘤浸润。
- SNR和CNR比较采用Mann-Whitney U检验,浸润组均显著高于无浸润组(P=0.004)。
临床应用与阅片要点
- 对于骨肉瘤患者,若需评估关节或胸膜腔有无肿瘤浸润,可考虑在ferumoxytol注射后24小时行MRI,观察积液是否出现T1强化。
- 注意:平扫、钆增强及注射后1小时ferumoxytol MRI均无法显示该强化差异,不宜用于判断浸润。
局限性
- 样本量小(15例患者,18次扫描),为初步探索性研究。
- 回顾性设计,部分病例(4例)浸润状态基于影像而非组织学确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The diagnosis of joint infiltration by a malignant bone tumor affects surgical management. The specificity of standard magnetic resonance imaging (MRI) for diagnosing joint infiltration is limited. During our MRI evaluations with ferumoxytol nanoparticles of pediatric and young adult patients with bone sarcomas, we observed a surprising marked T1 enhancement of joint and pleural effusions in some patients but not in others.
OBJECTIVE: To evaluate if nanoparticle extravasation differed between joints and pleura with and without tumor infiltration.
MATERIALS AND METHODS: We retrospectively identified 15 pediatric and young adult patients (mean age: 16±4 years) with bone sarcomas who underwent 18 MRI scans at 1 h (n=7) or 24 h (n=11) after intravenous ferumoxytol infusion. Twelve patients also received a gadolinium-enhanced MRI. We determined tumor invasion into the joint or pleural space based on histology (n=11) and imaging findings (n=4). We compared the signal-to-noise ratios (SNR) and contrast-to-noise ratios (CNR) of the joint or pleural fluid for tumors with and without invasion using a Mann-Whitney U test.
RESULTS: MRI scans 24 h after intravenous ferumoxytol infusion demonstrated a positive T1 enhancement of the effusion in all joints and pleural spaces with tumor infiltration and no joint or pleural space without infiltration. Corresponding SNR (P=0.004) and CNR (P=0.004) values were significantly higher for joints and pleural spaces with tumor infiltration than without. By contrast, unenhanced MRI, gadolinium-enhanced MRI and 1-h post-contrast ferumoxytol MRI did not show any enhancement of the joint or pleural effusion, with or without tumor infiltration.
CONCLUSION: This pilot study suggests that 24-h post-contrast ferumoxytol MRI scans can noninvasively differentiate between joints with and without tumor infiltration.
引用
- Theruvath AJ, Rashidi A, Nyalakonda RR, et al. Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients. Pediatr Radiol. 2021. PMID: 34410452. doi:10.1007/s00247-021-05156-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。